Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening Studies

Autor: Syrjänen, K., Shabalova, I., Naud, P., Kozachenko, V., Derchain, S., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto, Adhemar, Kljukina, L., Tatti, S., Branovskaja, M., Hammes, L. S., Branca, M., Grunjberga, V., Eržen, M., Juschenko, A., Costa, S., Sarian, L., Podistov, J., Syrjäen, S., Maeda, M. Y. S., NIS, LAMS Study Research Groups

Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

To make feasible future clinical trials with new-generation human papillomavirus (HPV) vaccines, novel virological surrogate endpoints of progressive disease have been proposed, including high-risk HPV (HR-HPV) persistence for six months (6M+) or 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1fff6e8868fe0751ec85b063b1c570d
https://doi.org/10.1258/ijsa.2009.009365

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.

Autor: Folschweiller N; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Teixeira J; University of Campinas, Campinas, Brazil., Joshi S; Jehangir Clinical Development Centre and Prayas, Pune, India., Goldani LZ; Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre Brazil., Supparatpinyo K; Chiang Mai University, Chiang Mai, Thailand., Basu P; Chittaranjan National Cancer Institute, Kolkata, India., Chotpitayasunondh T; Queen Sirikit National Institute of Child Health, Bangkok, Thailand., Chetchotisakd P; Khon Kaen University, Khon Kaen, Thailand., Ruxrungtham K; Chulalongkorn University and HIVNAT, TRC-ARC, Bangkok, Thailand., Roteli-Martins C; ABC Medical School, Santo André, São Paulo, Brazil., Grinsztejn B; Instituto de pesquisa Clínica Evandro Chagas (IPEC), Rio de Janeiro, Brazil., Quintana SM; Ribeirão Preto Medical School, University of São Paulo (USP), São Paulo, Brazil., Kumarasamy N; Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India., Poongulali S; Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India., Kulkarni V; Jehangir Clinical Development Centre and Prayas, Pune, India., Lin L; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Datta SK; GSK, Singapore, Singapore., Descamps D; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Dodet M; GSK, Rixensart, Belgium., Dubin G; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Friel D; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Hezareh M; Chiltern international for GSK, Wavre, Belgium., Karkada N; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Meric Camilleri D; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Poncelet S; GSK, Rixensart, Belgium., Salaun B; GSK, Rixensart, Belgium., Tavares-da-Silva F; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Thomas-Jooris F; GSK, Avenue Fleming 20, 1300 Wavre, Belgium., Struyf F; GSK, Avenue Fleming 20, 1300 Wavre, Belgium.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2020 May 25; Vol. 23, pp. 100353. Date of Electronic Publication: 2020 May 25 (Print Publication: 2020).

Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3

Autor: Syrjänen, K., Shabalova, I., Naud, P., Derchain, S., Sarian, L., Kozachenko, V., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto, Adhemar, Kljukina, L., Tatti, S., Branovskaja, M., Branca, M., Grunjberga, V., Erzen, M., Juschenko, A., Hammes, L. Serpa, Costa, S., Podistov, J., Syrjänen, S., NIS, LAMS Study Research Groups

Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

In addition to oncogenic 'high-risk' human papillomaviruses (HR-HPV), several co-factors are needed in cervical carcinogenesis, but it is poorly understood whether these HPV co-factors associated with incident cervical intraepithelial neoplasia (CIN)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b81e261ca1e883e879971f4d3afe383
https://hdl.handle.net/1822/67473

Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study

Autor: Syrjänen, K., Naud, P., Derchain, S., Roteli-Martins, C., adhemar longatto-filho, Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganca, J., Arlindo, F. C., Maeda, M. Y. S., Lörincz, A., Dores, G. B., Costa, S., Syrjänen, S.

Publikováno v: Scopus-Elsevier
Publons
ResearcherID
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

This is a European Commission (EC)-funded ongoing study known as the LAMS (Latin American Screening) study, where PAP smear/liquid-based cytology and screening colposcopy were compared with i) three optional screening tools [visual inspection with ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0f432733940ee425cf80a4dccfbc1ee8
https://hdl.handle.net/1822/67924

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.